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Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using
genetic variants as instruments for IGF peptides, we investigated whether these associations are likely to be causal. We
identified from the literature 56 single nucleotide polymorphisms (SNPs) in the IGF axis previously associated with bio-
marker levels (8 from a genome-wide association study [GWAS] and 48 in reported candidate genes). In ~700 men without
prostate cancer and two replication cohorts (N ~ 900 and ~9,000), we examined the properties of these SNPS as instru-
mental variables (IVs) for IGF-I, IGF-II, IGFBP-2 and IGFBP-3. Those confirmed as strong IVs were tested for association with
prostate cancer risk, low (< 7) vs. high ( 7) Gleason grade, localised vs. advanced stage, and mortality, in 22,936 controls
and 22,992 cases. IV analysis was used in an attempt to estimate the causal effect of circulating IGF peptides on prostate
cancer. Published SNPs in the IGFBP1/IGFBP3 gene region, particularly rs11977526, were strong instruments for IGF-II and
IGFBP-3, less so for IGF-I. Rs11977526 was associated with high (vs. low) Gleason grade (OR per IGF-II/IGFBP-3 level-
raising allele 1.05; 95% CI: 1.00, 1.10). Using rs11977526 as an IV we estimated the causal effect of a one SD increase in
IGF-II (~265 ng/mL) on risk of high vs. low grade disease as 1.14 (95% CI: 1.00, 1.31). Because of the potential for pleiot-
ropy of the genetic instruments, these findings can only causally implicate the IGF pathway in general, not any one specific
biomarker.
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Prostate cancer is the most common male cancer in industri-
alised countries, yet there are no established, potentially mod-
iﬁable risk factors for prevention.1 The nutritionally regulated
IGFs, and their modulating binding proteins (IGFBPs) play a
key role in somatic growth, and activate carcinogenic intra-
cellular signalling networks.1 Meta-analyses of epidemiologi-
cal studies generally observe positive associations of
circulating IGF-I with prostate cancer,2–4 but substantial dif-
ferences exist between studies.5,6
Such diverse evidence indicates that causation remains to
be established. Alternative explanations for the observed asso-
ciation of IGF-axis peptides with prostate cancer include:
reverse causality, because tumours may promote an endo-
crine response7; confounding by dietary,8 nutritional9 and
lifestyle10 factors; measurement error,11 as single serum meas-
urements may inadequately reﬂect long-term exposure; or
detection bias,11 occurring, for example, if IGF-I causes
symptomatic benign prostatic hyperplasia (BPH) that results
in the serendipitous ﬁnding of latent cancer on diagnostic
biopsy.
Mendelian randomization (MR)12 seeks to establish cau-
sality by using genetic variants as proxies for the exposure of
interest. Since alleles randomly assort at gamete formation
and segregate randomly at conception to generate genotypes,
associations between genotypes and outcome are not gener-
ally confounded by behavioural or environmental factors and
cannot be explained by reverse causation. Genetic variation
may also be a better measure of exposure over a lifetime
than a single serum measurement, as those with genotypes
causing high (or low) IGF levels will have been, in effect, ran-
domly allocated to high (or low) IGF levels from birth. To
determine causality, MR relies on an association between
genetic variant (also known as instrument) and exposure so
that the greater the correlation between the two, and thus the
more variation in the exposure phenotype explained by the
genotype, the more reliable the causal inference. Additionally,
the instrument is expected to inﬂuence the outcome only via
the exposure (i.e., absence of horizontal pleiotropy13) and to
be independent from confounders of the relationship between
exposure and outcome.
We used an MR approach in an attempt to assess the
causal role of the IGF axis in prostate cancer. First, we vali-
dated genetic variants previously associated with IGF levels
in the literature to conﬁrm reported associations of the SNPs
(especially SNPs selected from candidate gene studies), and
to assess the potential for pleiotropic effects of the genetic
variants on more than one IGF protein. Second, we per-
formed a large case–control study based on an international
prostate cancer consortium of >22,000 case/control pairs
using the validated polymorphisms.
Material and Methods
Study populations
ProtecT (Prostate testing for cancer and Treatment)
study. The association of genetic variants with IGF levels
was evaluated in the control arm of a case–control study
nested within ProtecT, a UK multicentre study to identify
localised prostate cancer and evaluate its management in a
randomly allocated controlled trial.5 All men without evi-
dence of prostate cancer were eligible for selection as con-
trols; that is, men with a prostate speciﬁc antigen (PSA)
test< 3 ng/mL, or men with a raised PSA ( 3 ng/mL) com-
bined with at least one negative diagnostic biopsy. Of the
2,766 controls who underwent measures of IGFs in ProtecT5,
700 men also had genome-wide genotype data available
(mean age6 SD: 62.16 5.0 years).
Blood samples for IGF measurement in ProtecT were
drawn at the time of the PSA test, frozen at 2808C within 36
hr, then transferred on dry ice for assay.4 Total IGF-I, IGF-II
and IGFBP-3 levels were measured by in-house radioimmu-
noassay (RIA) and circulating IGFBP-2 was measured using
a one-step sandwich ELISA (DSL-10–7100; Diagnostic Sys-
tems Laboratories). The intra-class correlations (ICC) for
within-assay variability for IGF-I, IGF-II, IGFBP-2 and
IGFBP-3 were 0.86, 0.91, 0.95 and 0.88; the ICCs for
between-assay variability were 0.66, 0.84, 0.81 and 0.71,
respectively.
Genome-wide genotyping of participants was carried out
at the Centre National de Genotypage (CNG, Evry, France),
using the Illumina Human660W-Quad_v1_A array (Illumina
Inc., San Diego, CA). The quality control (QC) process per-
formed before imputation excluded individuals on the basis
of the following: sex mismatches, minimal (< 0.325) or
excessive (> 0.345) heterozygosity, disproportionate levels of
individual missingness (> 3%), cryptic relatedness measured
as a proportion of identity by descent (IBD> 0.1), and insuf-
ﬁcient sample replication (IBD< 0.8). All individuals with
non-European ancestry, and SNPs with a minor allele fre-
quency (MAF) below 1%, a call rate of< 95% or out of
Hardy-Weinberg equilibrium (p< 5 3 1027) were removed.
Autosomal genotypic data were imputed using Markov Chain
Haplotyping software (MACH v.1.0.16)14 and phased
What’s new?
Circulating insulin-like growth factors (IGF) and their binding proteins have been associated with prostate cancer risk in obser-
vational epidemiological studies but it is not clear whether there is a causal relationship with disease. To address this ques-
tion, the authors used Mendelian randomization, a method that uses genetic variants as proxies for measured exposures.
Their results implicate the IGF pathway in general in prostate cancer development but specific biomarkers remain to be
determined.
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haplotype data from European (CEU) individuals (HapMap
release 22, Phase II NCBI B36, dbSNP 126) based on 514,432
autosomal SNPs. After imputation, all SNPs with indication
of poor imputation quality (r2 hat< 0.3) were eliminated.
The working dataset consisted of 2,927 individuals (1,136
cases, 1,791 controls) of European ancestry.
Trent Multicenter Research Ethics Committee (MREC)
approved both the ProtecT study (MREC/01/4/025), and the
associated ProMPT study which collected biological material
(MREC/01/4/061). Written informed consent was obtained
from all men.
ALSPAC (Avon Longitudinal Study of Parents and
Children). We used ALSPAC to replicate ProtecT ﬁndings.
ALSPAC is a population-based prospective cohort study of
children and their parents. The study is described in detail
elsewhere15–17 (http://www.bristol.ac.uk/alspac/). Measure-
ment of circulating IGF-I, IGF-II and IGFBP-3 in plasma or
serum was carried out as in ProtecT. IGFBP-2 was not meas-
ured. The intra- and inter-assay coefﬁcients of variation (CV)
were 7.0 and 14.3% for IGF- I, 7.9 and 18.6% for IGF-II, and
6.1 and 8.7% for IGFBP-3.18
Genome-wide association study (GWAS) data for the chil-
dren were generated by Sample Logistics and Genotyping
Facilities at the Wellcome Trust Sanger Institute (Cambridge,
UK) and the Laboratory Corporation of America (Burlington,
NC, USA) with support from 23andMe (Mountain View,
CA, USA) using the Illumina HumanHap550 quad chip. The
mothers were genotyped at CNG using the Illumina
Human660W quad array. All individuals of non-European
ancestry, ambiguous sex, extreme heterozygosity, cryptic
relatedness (IBD> 0.1 in children,> 0.125 in mothers), high
missingness (> 3% in children,> 5% in mothers) and insufﬁ-
cient sample replication (IBD< 0.8) were removed. SNPs
with genotyping rate< 95%, MAF< 1%, or out of Hardy-
Weinberg equilibrium (p< 5 3 1027 in children, p< 1 3
1026 in mothers) were excluded. Genotypic data was subse-
quently phased with ShapeIT v2.r644,19 and imputed using
IMPUTE v2.2.220 and phased haplotype data from the 1000
Genomes reference panel (phase 1, version 3), based on
465,740 SNPs. The cleaned dataset consisted of 8,237 chil-
dren and 8,196 mothers. Up to 400 pregnant women
(mean6 SD age at delivery: 28.76 5.4 years) and 450 chil-
dren at different ages (mean6 SD age: 61.86 0.8 months,
54% male; 7.56 0.2 years, 54% male; 8.26 0.1 years, 56%
male), as well as 500 umbilical cord samples had genotypes
and IGF measures for analysis.
Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local Research
Ethics Committees (http://www.bristol.ac.uk/alspac/research-
ers/data-access/ethics/lrec-approvals/#d.en.164120). Written
informed consent was obtained from all participants in the
study.
Understanding Society: the UK Household Longitudinal Study
(UKHLS). SNPs validated in ProtecT were also examined in
the UKHLS study, which is a stratiﬁed clustered random
sample of households, representative of the UK population
(https://www.understandingsociety.ac.uk/). Serum IGF-I levels
were measured using an electrochemiluminescent immunoas-
say on an IDS ISYS analyser. The inter- and intra-assay C vs.
were< 14%. No measurements of IGF-II, IGFBP-2 or
IGFBP-3 were available.
In total, 10,480 samples were genotyped on the Illumina
HumanCoreExome chip (v1.0) at the Wellcome Trust Sanger
Institute. Data QC was performed at the sample-level using
the following ﬁlters: call rate< 98%, autosomal heterozygosity
outliers (> 3 SD), gender mismatches, duplicates as estab-
lished by IBD analysis (PI_HAT> 0.9), ethnic outliers. Var-
iants with a Hardy-Weinberg equilibrium p values< 1024, a
call rate below 98% and poor genotype clustering values (<
0.4) were removed, as well as mitochondrial polymorphisms,
leaving 518,542 variants. Imputation was performed at the
UCL Genetics Institute using Minimac version 5–29-12,21
MaCH14 for phasing, and the 1000 Genomes Project, March
2012, version 3, NCBI build GRCh37/hg19 as a reference
sample. The ﬁnal sample consisted of 9,944 individuals. As
UKHLS is a household study we additionally eliminated indi-
viduals who were related (> 5%), thus the working sample
included 9,237 participants (mean6 SD age: 54.16 16.1
years, 44% male).
UKHLS is designed and conducted in accordance with the
ESRC Research Ethics Framework and the ISER Code of
Ethics. The University of Essex Ethics Committee approved
waves 1–5 of UKHLS. Approval from the National Research
Ethics Service was obtained for the collection of biosocial
data by trained nurses in waves 2 and 3 of the main survey
(Oxfordshire A REC, Reference: 10/H0604/2).
PRACTICAL Consortium (PRostate cancer AssoCiation group to
Investigate Cancer-Associated aLterations in the genome).
We investigated associations of published IGF-related genetic
variants, evaluated as instruments in ProtecT and replicated
in ALSPAC and/or UKHLS, with prostate cancer risk, pro-
gression and mortality in men from 25 studies contributing
to the international PRACTICAL consortium22 (http://practi-
cal.ccge.medschl.cam.ac.uk). Seventeen studies were from
Europe, six from North America and two from Australia,
and comprised population samples of predominantly Euro-
pean ancestry22 (Table 1). Data on cancer stage, grade and
method of diagnosis were collected by each study using a
variety of methods. We categorised cancers as localised (T1
or T2 on TNM staging, or if not available, “localised” on
SEER staging) or advanced (T3 or T4, or “regional” or
“distant” on SEER staging).
Genotyping of PRACTICAL samples was carried out
using an Illumina Custom Inﬁnium genotyping array
(iCOGS), designed for the Collaborative Oncological Gene-
Environment Study (COGS) (http://www.cogseu.org/) and
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consisting of 211,155 SNPs.22 This array was devised to eval-
uate associations of genetic variants with breast, ovarian and
prostate cancer (85,278 were speciﬁcally chosen for their
potential relevance to prostate cancer). A total of 201,598
SNPs passed QC for the European ancestry samples.22 Impu-
tation of 17 million SNPs/indels using the 1000 Genomes
Project (version 3, March 2012 release) as a reference panel
was performed with the program IMPUTE v.2.20 Polymor-
phisms with quality information scores of (r2)> 0.3 and
MAF> 0.5 were taken forward for analysis.23 Overall there
were 22,992 prostate cancer cases and 22,936 controls with
genotype data available.
All studies have the relevant Institutional Review Board
approval in each country in accordance with the Declaration
of Helsinki.
Identification of genetic variants associated with IGF levels
in the literature
We selected single nucleotide polymorphisms (SNPs) associ-
ated with circulating IGF levels from the National Human
Genome Research Institute-European Bioinformatics Institute
(NHGRI-EBI) catalog of genome-wide association studies
(GWAS) (https://www.ebi.ac.uk/gwas/) and by conducting a
PubMed literature search. All SNPs chosen were associated
Table 1. Clinical characteristics of prostate cancer cases in 25 PRACTICAL studies
Study Country
N
controls
N
cases
Mean age
at diagnosis
(years)
Mean PSA
at diagnosis
(ng/mL)
European
ethnicity
(%)1
Family
history
of prostate
cancer (%)1,2
High
Gleason
score
(7, %)1
Advanced
stage (%)1,3
Screen-
detected
cancer (%)1
CAPS Sweden 664 1153 66.1 79.6 100 17.4 49.92 30.3 0.0
CPCS1 Denmark 2756 848 69.5 48.0 99.6 8.22 71.22 n/a 0.0
CPCS2 Denmark 1001 265 64.9 36.0 99.4 14.72 52.22 n/a 0.0
EPIC Europe 1079 722 64.9 0.2 100 n/a 27.92 4.02 0.0
EPIC-Norfolk UK 911 481 72.1 n/a 99.9 2.5 39.42 n/a n/a
ESTHER Germany 318 313 65.5 58.7 100 8.92 48.0 27.6 61.92
FHCRC USA 729 761 59.7 16.1 99.9 21.7 41.7 20.2 N/a
IPO-Porto Portugal 66 183 59.3 8.3 100 20.02 84.2 64.5 82.82
MAYO USA 488 767 65.2 15.5 100 29.1 55.32 45.5 73.72
MCCS3 Australia 1169 1650 58.5 18.8 98.8 23.52 53.4 14.5 N/a
MEC USA 829 819 69.5 n/a 100 13.0 n/a 12.5 N/a
MOFFITT USA 96 404 65.0 7.3 97.5 22.3 43.4 3.6 0.02
PCMUS Bulgaria 140 151 69.3 32.5 100 5.3 59.6 46.7 21.2
Poland Poland 359 438 67.7 40.2 100 10.6 32.82 37.12 0.02
PPF-UNIS UK 187 244 68.9 32.1 99.8 25.3 45.22 28.82 N/a
ProMPT UK 2 166 66.3 33.0 100 34.6 74.32 34.7 0.02
ProtecT UK 1458 1545 62.7 9.6 99.7 8.02 29.9 11.4 100.0
QLD Australia 85 139 61.4 7.4 99.14 37.8 83.6 0.02 N/a
SEARCH UK 1231 1354 63.1 53.2 100 16.3 56.92 18.02 36.72
STHM1 Sweden 2224 2006 66.2 n/a 100 20.2 45.52 14.42 N/a
TAMPERE Finland 2413 2754 68.2 69.2 100 n/a 43.82 21.4 46.8
UKGPCS UK 4132 3838 63.6 88.0 99.8 22.42 50.52 36.42 28.02
ULM Germany 354 603 63.8 19.1 100 44.9 51.32 40.5 N/a
UTAH USA 245 440 62.6 n/a 100 51.4 n/a 17.22 N/a
WUGS USA 0 948 60.8 6.1 95.8 42.62 59.3 24.2 N/a
N545,928 men.
Information in the table is given for the subset of individuals whose ethnicity was “European” (except for the study’s European ethnicity
percentage).
1Percent of cases with data available.
Family history of prostate cancer in a first degree relative.
T3 or T4 on TNM staging, or if not available, “regional” or “distant” on SEER staging.
2Information missing for >10% of patients.
3MCCS includes Risk Factors for Prostate Cancer Study (RFPCS) and The Early Onset Prostate Cancer Study (EOPCS).
4Information missing for >10% of individuals.
n/a not available.
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with IGF concentration at the signiﬁcance thresholds estab-
lished by each study (p< 5 3 1027 in the discovery GWAS;
usually p< 0.05 in candidate gene studies).
Validation of genetic variants as instruments of IGF levels
The properties of the SNPs as instrumental variables (IV)
were assessed in ProtecT controls by examination of: (i) F
statistics (with values lower than 10 taken as evidence of a
weak instrument24) and R2 values (the proportion of varia-
tion in IGF levels explained by the genetic variant) from the
linear regression of each biomarker on the SNP; (ii) associa-
tions of the genetic variants with potential confounding fac-
tors and other variables (age, PSA at recruitment, body mass
index (BMI), height, leg-length, BPH and diabetes); and (iii)
possible pleiotropic effects of the variants on more than one
IGF peptide.25 The validated genetic instruments were tested
for replication in ALSPAC mothers and children, and
UKHLS participants.
Statistical analysis
All SNPs were examined for deviation from Hardy-Weinberg
equilibrium using the hwsnp function in the statistical pack-
age Stata. Linear and logistic regression were used as appro-
priate to investigate the effect of SNPs on IGF-I, IGF-II,
IGFBP-2, IGFBP-3, PSA and potential confounders. For the
validated SNPs we ran meta-analyses across all PRACTICAL
studies to evaluate between-study heterogeneity in the associ-
ation with prostate cancer risk, Gleason grade (low: <7 vs.
high: 7) and stage (localised vs. advanced). We computed
pooled ORs assuming a ﬁxed-effects model when there was
no evidence of heterogeneity (p> 0.05), otherwise we used a
random-effects model. Logistic regression with robust stand-
ard errors, to account for within-study clustering, was per-
formed to test for associations of all polymorphisms across
the IGFBP1/IGFBP3 region and SNPs in other chromosomal
regions with the above prostate cancer outcomes.
Linkage disequilibrium (LD) between pairs of variants in
the IGFBP-1/IGFBP-3 gene region was calculated with the
program LDlink using data for the GBR population (English
and Scottish) in Phase 3 of the 1,000 Genomes Project.26 r2
values obtained with LDlink were then used to create an LD
plot of the region with the R package LDheatmap (http://
www.R-project.org). Functional consequences of genetic poly-
morphisms were predicted using SNPnexus (http://www.snp-
nexus.org/).
Survival analysis. Amongst men with prostate cancer, we
estimated associations of the validated SNPs with long-term
(15-year) survival, examining all-cause and prostate cancer-
speciﬁc mortality using Cox proportional hazards regression
with date at diagnosis as the start date and date at death or
ﬁnal follow-up time-point as the exit date, with robust stand-
ard errors to account for within-study clustering.
Instrumental variable (IV) analysis. To estimate the causal
effect of IGF levels on prostate cancer, we used validated
SNPs as the instruments in a two-sample ratio estimator IV
analysis27,28 (Fig. 1). The ratio represents the causal log odds
ratio of a one unit increase in circulating IGF on the risk of
prostate cancer. IV analysis was conducted for the SNPs
showing the strongest association with prostate cancer, which
were also associated with circulating IGFs in ProtecT,
ALSPAC or UKHLS, and the estimates are given per stand-
ard deviation (SD) increase in IGF levels.
Adjustments. Principal components reﬂecting each popula-
tion’s genetic structure were included as covariates in the
regression models to account for confounding by population
stratiﬁcation. Additional adjustments for age at diagnosis, age
at blood sample collection, gestational age and sex were
made when appropriate.
Unless otherwise speciﬁed, all analyses were carried out in
Stata version 13 (StataCorp LP, 2013, College Station, TX).
Figure 1. Directed acyclic graph (DAG) showing the instrumental variable (IV) assumptions underpinning a Mendelian randomization analy-
sis of circulating IGF levels with prostate cancer. IV models use associations A and B to estimate the causal effect of IGF on prostate cancer
C (C5B/A). The instrument is assumed not to have a direct effect on the outcome, hence the dashed line is to illustrate that association B
is required for IV estimation. The effect of genotype on the outcome should be mediated only through the intermediate phenotype (no plei-
otropy). The numerator of the two sample IV estimator is the log odds ratio from a logistic regression of the outcome (Y) on the instrument
(Z) in the PRACTICAL population and the denominator is the beta coefficient from a linear regression of the exposure (X) on the instrument
(Z) in the ProtecT or UKHLS population or obtained from the literature.
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Table 2. Association of published SNPs with IGF biomarkers in ProtecT controls
ProtecT: effect on published biomarkers ProtecT: effect on other biomarkers
SNP
Effect allele/
non-effect
allele1
Published
associations
Mean difference
in IGF levels
(ng/mL) per
effect allele 95% CI p value
Other
associations
Mean difference
in IGF levels
(ng/mL) per
effect allele 95% CI p value F R2 (%)
rs3770473 G/T IGF-I 1.06 (28.77,10.89) 0.83
IGFBP-3 243.89 (2225.24,137.47) 0.64
rs300982 G/A IGFBP-3 2139.80 (2420.66, 141.05) 0.33
rs4234798 T/G IGFBP-3 249.51 (2165.48,66.45) 0.40
rs7703713 A/G IGF-I 21.32 (28.14,5.49) 0.70 IGFBP-2 20.07 (20.14, 20.001) 0.04 2.5 0.34
rs2153960 A/G IGF-I 3.67 (23.16,10.49) 0.29 IGFBP-2 0.07 (0.002,0.14) 0.04 3.6 0.50
rs998075 G/A IGF-I 1.78 (24.14,7.71) 0.56
rs998074 C/T IGF-I 1.78 (24.14,7.71) 0.56
rs7780564 C/A IGF-I 4.35 (21.46,10.15) 0.14
rs10228265 A/G IGFBP-3 211.25 (2126.51,104.00) 0.85 IGF-II 27.31 (21.71,56.33) 0.07 3.8 0.52
rs1908751 T/C IGF-I 20.40 (26.98,6.18) 0.91
rs2270628 C/T IGFBP-3 3.35 (2129.87,136.56) 0.96 IGF-II 34.97 (1.40,68.54) 0.04 4.9 0.68
rs6670 T/A IGF-I 25.62 (214.58,3.35) 0.22
rs3110697 G/A IGFBP-3 234.10 (2144.90,76.69) 0.55 IGF-II 55.26 (27.60,82.92) 9.64x1025 14.3 1.94
rs9282734 G/T IGFBP-3 360.75 (2574.69,1296.20) 0.45
rs2471551 G/C IGFBP-3 7.96 (2128.43,144.34) 0.91 IGF-I 9.03 (21.65,16.42) 0.02 5.6 0.76
IGF-II 244.24 (278.55, 29.93) 0.01 6.0 0.82
rs2132572 C/T IGFBP-3 252.69 (2180.87,75.48) 0.42 IGF-II 35.09 (2.79,67.38) 0.03 4.3 0.59
IGF-I 24.32 (211.30,2.65) 0.22
rs2132571 C/T IGFBP-3 62.68 (253.82,179.19) 0.29 IGF-II 55.35 (26.15,84.55) 2.14x1024 11.6 1.58
IGF-I 6.79 (0.45,13.13) 0.04 4.0 0.54
rs924140 T/C IGFBP-3 13.33 (297.43,124.10) 0.81 IGF-II 76.49 (49.08,103.89) 5.92x1028 26.0 3.47
rs1496499 G/T IGF-I2 3.12 (22.48,8.72) 0.27 IGF-II 77.18 (49.81,104.55) 4.35x1028 26.3 3.52
rs11977526 A/G IGFBP-3 83.98 (231.18,199.14) 0.15 IGF-II 94.78 (66.48,123.09) 9.53x10211 37.8 4.98
IGF-I2 3.07 (22.77,8.91) 0.30
rs700752 G/C IGF-I 9.22 (3.19,15.24) 0.003 7.7 1.05
IGFBP-3 219.21 (108.61,329.81) 1.09x1024 13.6 1.86
rs1245541 G/A IGF-I 20.79 (26.93,5.34) 0.80
rs217727 A/G IGF2 14.65 (220.09,49.39) 0.41 IGFBP-3 135.16 (22.00,272.33) 0.053 2.0 0.28
rs6214 T/C IGF-I 2.64 (23.51,8.79) 0.40
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Table 2. Association of published SNPs with IGF biomarkers in ProtecT controls (Continued)
ProtecT: effect on published biomarkers ProtecT: effect on other biomarkers
SNP
Effect allele/
non-effect
allele1
Published
associations
Mean difference
in IGF levels
(ng/mL) per
effect allele 95% CI p value
Other
associations
Mean difference
in IGF levels
(ng/mL) per
effect allele 95% CI p value F R2 (%)
rs1520220 G/C IGF-I 6.37 (21.88,14.61) 0.13
rs5742694 A/C IGF-I 25.59 (212.74,1.56) 0.13
rs978458 T/C IGF-I 5.22 (21.79,12.23) 0.14
rs5742678 C/G IGF-I 5.22 (21.79,12.23) 0.14
rs972936 C/T IGF-I 25.22 (212.23,1.79) 0.14
rs2288378 T/C IGF-I 5.60 (21.55,12.74) 0.12
rs7136446 C/T IGF-I 3.81 (22.19,9.81) 0.21
rs10735380 G/A IGF-I 6.13 (20.71,12.96) 0.08 3.4 0.47
rs2195239 G/C IGF-I 5.89 (21.35,13.13) 0.11
rs12821878 G/A IGF-I 6.93 (20.18,14.05) 0.06 3.2 0.43
rs5742615 T/G IGF-I 3.99 (228.62,36.60) 0.81
rs2162679 T/C IGFBP-3 238.78 (2201.52,123.96) 0.64
rs5742612 G/A IGF-I 28.36 (225.99,9.26) 0.35
IGFBP-3 281.73 (2409.99,246.53) 0.63
rs35767 A/G IGF-I 1.27 (27.47,10.01) 0.78
IGFBP-3 38.78 (2123.96,201.52) 0.64
rs35766 C/T IGF-I 3.58 (24.85,12.02) 0.41
rs35765 T/G IGF-I 6.45 (23.14,16.04) 0.19
rs7965399 C/T IGF-I 24.86 (220.59,10.86) 0.54
rs11111285 G/A IGF-I 24.96 (220.73,10.80) 0.54
IGFBP-2 0.003 (20.15,0.16) 0.97
rs855211 A/G IGF-I 2.50 (25.75,10.75) 0.55
rs10778177 C/T IGF-I 21.22 (29.80,7.36) 0.78
rs855203 C/A IGF-I 2.52 (27.95,12.99) 0.64
rs1457596 A/G IGF-I 2.94 (27.83,13.71) 0.59
rs7964748 A/G IGF-I 1.25 (26.44,8.94) 0.75
rs907806 G/A IGFBP-3 2112.72 (2285.09,59.66) 0.20
rs213656 T/G IGF-I 4.32 (21.66,10.30) 0.16 IGFBP-2 20.06 (20.12,0.00) 0.05 4.1 0.56
rs3751830 C/T IGF-I 3.23 (22.80,9.26) 0.29 IGFBP-2 20.05 (20.11,0.01) 0.09 3.3 0.44
rs197056 A/G IGF-I 6.70 (0.61,12.78) 0.03 IGFBP-2 20.06 (20.12,0.00) 0.06 3.6 0.50
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Results
We identiﬁed 56 SNPs that were associated with circulating
IGF peptides in GWAS (n5 8) or candidate gene studies
(n5 48) (Supporting Information Table 1). Most of these
SNPs were located in the IGF1 and IGFBP1/IGFBP3 gene
regions on chromosomes 12q23.2 and 7p12.3, respectively,
and showed associations with IGF-I and IGFBP-3 levels. We
could only ﬁnd one candidate gene study that had examined
the relationship of blood IGF-II with genetic polymor-
phisms,29 and one that had similarly considered IGFBP-2
concentrations.30
Validation of the association of published SNPs with IGF
levels in ProtecT controls
IGF-I, IGF-II and IGFBP-3 blood concentrations were
approximately normally distributed, as opposed to IGFBP-2,
which was natural log-transformed for analysis. Mean (6
SD) levels are given in Supporting Information Table 2. All
SNPs, with the exception of rs3770473 (p< 0.0001), con-
formed with Hardy-Weinberg equilibrium. Six SNPs in the
IGFBP1/IGFBP3 gene region were strongly associated with
circulating IGFs (F-statistic> 10),31 individually explaining
2 – 5% of variation in biomarker concentration (Table 2).
The genetic variant showing the strongest association, and
thus ranking as the best instrument, was rs11977526 (F5 38,
R25 5%), the lead SNP in a GWAS of IGF-I and IGFBP-3
levels.32 Five out of the six SNPs (including rs11977526) were
not associated with the IGF biomarker reported in the litera-
ture but with IGF-II instead. Only one SNP (rs700752) was
consistent with published reports, showing associations with
both IGF-I and IGFBP-3 (although it qualiﬁed as a strong
instrument only for IGFBP-3) (Table 2). Three of the most
robustly associated variants (rs11977526, rs1496499,
rs700752) had been identiﬁed in a GWAS including over
10,000 participants,32 and the remaining three (rs3110697,
rs2132571, rs924140) were in strong LD with the ﬁrst two
(Supporting Information Fig. 1).
Other SNPs identiﬁed in the same GWAS, but located in
different chromosomal regions, were either not associated
with the serum concentration of any biomarker (rs4234798,
rs7780564 and rs1245541), marginally associated with a bio-
marker other than the one reported in the GWAS (rs2153960
with IGFBP-2 instead of IGF-I), or showed an association
with the GWAS-reported biomarker (IGFBP-3) but did not
satisfy the requirements of a strong instrument (rs1065656)
(Table 2).
The validated SNPs were not correlated with potential
confounders or PSA, after applying a Bonferroni correction
for multiple testing (p values> 0.001) (Supporting Informa-
tion Table 3).
Replication in ALSPAC
Mean (6 SD) levels of IGF-I, IGF-II and IGFBP-3 for moth-
ers and children are shown in Supporting Information TableTa
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2. All SNPs that were strong instruments for IGF-II in Pro-
tecT (rs11977526, rs1496499, rs2132571, rs3110697,
rs924140) plus two extensively studied functional variants
rs2854744 (2202 A/C) and rs2854746 (Gly32Ala) that were
not genotyped or imputed in ProtecT and are in strong LD
with rs11977526 (r25 0.66 for rs2854744 and 0.98 for
rs2854746 in the UK population), were replicated with
respect to IGF-II levels in ALSPAC. The strongest instru-
ments were: rs2854746, explaining between 2.5% (in cord
blood samples) and 11.4% (in 61 month-old children) of var-
iation in IGF-II; and rs11977526, explaining 4.3% of variation
in maternal IGF-II. Unlike in ProtecT, and in agreement
with the literature, these SNPs were generally also associated
with IGFBP-3 levels, although not as strongly as with IGF-II.
The strongest instruments for IGFBP-3 were rs2854746
(R25 4.9% in mothers), rs1496499 (R25 6.1% in children)
and rs700752 (R25 4.1% in children) (Supporting Informa-
tion Table 4). No strong associations with IGF-I were uncov-
ered. SNPs identiﬁed in the discovery GWAS, not on 7p12.3,
were weakly or not at all (rs7780564) associated with IGF
levels (Supporting Information Table 5).
Replication in UKHLS
Mean (6 SD) IGF-I concentrations for men and women who
participated in UKHLS are shown in Supporting Information
Table 2, whilst association results are displayed in Supporting
Information Table 4. All SNPs, with the exception of
rs2132571, were associated with serum IGF-I. SNPs that were
in strong LD (i.e., all excluding rs700752) showed associa-
tions consistent with those reported in the literature,
although in the literature their effects were adjusted for
IGFBP-3 levels, which we could not do in UKHLS as circu-
lating IGFBP-3 was not available. Variants rs700752,
rs11977526 and rs2854746 qualiﬁed as strong instruments for
IGF-I levels (F> 10) but did not appear to explain much of
the variance in the trait. Results for other GWAS-identiﬁed
variants can be found in Supporting Information Table 5.
Association of validated SNPs with prostate cancer risk
and progression in PRACTICAL
Fixed-effects and random-effects meta-analyses of the eight
validated polymorphisms identiﬁed stronger associations with
prostate cancer grade than with risk or disease stage (Table 3).
). Rs11977526 (the strongest instrument) was associated with
high Gleason grade (OR per A allele 1.05; 95% CI: 1.00, 1.10)
(Supporting Information Fig. 2). This variant’s A (minor)
allele was associated with increased IGF-II levels in ProtecT
and ALSPAC, IGFBP-3 levels in the literature and ALSPAC,
and with reduced IGF-I levels in UKHLS. Other SNPs in the
region in LD with rs11977526 had a similar effect on disease
grade (Table 3). The major allele in rs700752, which is asso-
ciated with higher IGF-I levels, showed a weakly protective
effect with respect to high grade prostate cancer (OR per G
allele 0.97; 95% CI: 0.92, 1.01) (Supporting Information Fig. Ta
b
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3). Evidence of association is limited when a Bonferroni cor-
rection for multiple testing is applied.
Survival analysis in PRACTICAL
Rs700752 was associated with prostate cancer-speciﬁc mortal-
ity, with the allele that increases IGF-I and IGFBP-3 levels
(major) being associated with a lower risk of death. No other
associations with all-cause or prostate cancer-speciﬁc mortal-
ity were observed, except when considering the non-additive
relationship of the genetic variant with survival (Supporting
Information Table 6). In the case of SNPs linked to
rs11977526 (i.e., rs1496499, rs2854744, rs2854746 and
rs924140) heterozygotes exhibited the highest mortality rates,
compared to homozygotes. The proportional hazards
assumption was not fulﬁlled for many of the variants
(p< 0.05).
Instrumental variable analysis
An IV analysis using individual-level data was run for
rs11977526 and IGF-II, as it had been genotyped/imputed in
both ProtecT and PRACTICAL, and showed associations
with circulating IGF-II in ProtecT and prostate cancer grade
in PRACTICAL. The estimated causal OR per one SD (265
ng/mL) increase in serum IGF-II was 1.14 (95% CI: 1.00,
1.31) for high (vs. low) grade disease. Similarly, using infor-
mation from UKHLS on the association between rs11977526
and IGF-I, we estimated a causal OR of 0.39 (95% CI: 0.14,
1.10) per one SD (50 ng/mL) increase in circulating IGF-I
for high Gleason grade cancer.
We used summary data for the association of rs11977526
with IGFBP-3 from the discovery GWAS32 (results from the
Framingham Heart Study cohort as the largest study) and its
association with Gleason grade in PRACTICAL, to estimate
the causal OR per one SD (1000 ng/mL) increase in
IGFBP-3 as 1.15 (95% CI: 1.00, 1.32) for high (vs. low) grade
disease.
Finally, if rs700752 is employed as an IV for serum IGF-I
and IGFBP-3, based on ProtecT ﬁndings, the causal estimates
regarding prostate cancer-speciﬁc mortality were HR 0.72
(95% CI: 0.53, 0.98) per SD increase in IGF-I, and HR 0.76
(95% CI: 0.60, 0.95) per SD increase in IGFBP-3. Considering
UKHLS as the source of the SNP-exposure effect, the causal
estimate per SD increase in IGF-I levels was lower but com-
parable, HR 0.47 (95% CI: 0.29, 0.82).
Further analysis (see Supporting Information Results)
In order to obtain a more complete picture of the IGFBP1/
IGFBP3 genetic region and its relationship to prostate cancer,
we carried out an analysis of all additional SNPs within these
genes that were available in PRACTICAL (n5 39).
We also examined the association of non-validated SNPs
from the discovery GWAS with prostate cancer risk, progres-
sion and mortality.
Discussion
We found that variants that had been identiﬁed in a
GWAS32 and others linked to them, were the strongest
instruments for the exposures examined, as expected. Surpris-
ingly, in ProtecT most of these variants were strong instru-
ments for a related exposure (i.e., IGF-II) and not for the
exposure for which they were originally described (i.e., IGF-I
and IGFBP-3). The discovery GWAS did not analyse IGF-II
or other IGBP proteins besides IGFBP-3, which the authors
considered a limitation of their study. Additionally, all the
variants that proved to be strong instruments for serum IGFs
were located on chromosome 7p12.3 in the IGFBP1/IGFBP3
gene region. This is consistent with the dominant effect of
IGFBP-3 on circulating IGF levels. The IGFs are not stored
in any tissue but are constitutively secreted from most tissues
and stored in a circulating reservoir by forming a ternary
complex with IGFBP-3 and an acid labile subunit that
extends the circulating half-life of IGFs from 8–12 minutes to
15–18 hr.33
To investigate the discrepancy between our ﬁndings in
ProtecT and the literature reports, we ran an analysis of
SNPs conﬁrmed as strong instruments in ProtecT, in
ALSPAC mothers (N  400) and children (N  160–450)
who had IGF-I, IGF-II and IGFBP-3 measured, and in
9,000 men and women from the UKHLS with measures of
circulating IGF-I. Robust associations of IGFBP1/IGFBP-3
SNPs with IGF-II as well as with IGFBP-3 levels were identi-
ﬁed in pregnant women and in children across several ages.
None of the SNPs were associated with IGF-I in ALSPAC.
However, in UKHLS the majority of these variants showed
an association with IGF-I concentration, the most convincing
being rs700752.
The remaining GWAS-identiﬁed IGF-associated variants
on chromosomes 4p16.1, 6q21, 7p21.3, 10q22.1 and 16p13.3
were not strong instruments in ProtecT, ALSPAC or UKHLS.
When examined in relation to prostate cancer, the vali-
dated IGF instruments showed weak associations with Glea-
son grade. The strongest instrument in the literature and in
ProtecT, rs11977526 and other SNPs in LD with it were asso-
ciated with high (vs. low) grade disease. In addition, a few of
the strong instruments validated in this study were associated
with all-cause mortality under a non-additive genetic model
(on the basis on an earlier report of non-additivity in the
relationship of rs11977526 and longevity34). On the other
hand, rs700752 exhibited the strongest association with pros-
tate cancer-speciﬁc mortality under an additive model.
The non-validated instruments from the discovery
GWAS32 did not show an association with any prostate can-
cer outcome, except for rs2153960, which was associated with
aggressiveness and mortality. This SNP lies in the FOXO3
gene, well-known for its relationship with longevity,35 and it
is possible that this is driving the association with cancer.
A deeper look into the IGFBP1/IGFBP3 region revealed at
least two independent signals of association with prostate
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cancer following the regional LD structure (excluding
rs700752): one toward the IGFBP1 gene, and one encompass-
ing the IGFBP3 gene. The lack of –or marginal- association
with IGF-I, IGF-II and IGFBP-3 levels of SNPs in or near
IGFBP1 may mean that these variants are predominantly
inﬂuencing IGFBP-1 levels. Recently higher circulating
IGFBP-1 was found to be associated with lower prostate can-
cer risk.4,36 It is also conceivable that these signals may all be
linked to another, causal signal in the region.
An MR analysis using rs11977526 as the IV, revealed that
a large increase in the concentration of IGF-II or IGFBP-3
(1 SD) would increase the likelihood of progression to high
grade cancer by approximately 15%, whilst a similar increase
in IGF-I levels would be protective against disease progres-
sion. Conversely, if rs700752 (a SNP not in LD with, and
quite distant from rs11977526) is used as an instrument for
IGF levels, a one SD increase in IGF-I or IGFBP-3 would
reduce the risk of prostate cancer-speciﬁc mortality between
25% and 50%, depending on the genotype-exposure esti-
mates considered. Given the association of each SNP with
multiple IGF biomarkers the estimates obtained using differ-
ent sets of instruments and exposures could provide fairly
different answers.
In summary, we have conﬁrmed the association of genetic
variants that lie toward the IGFBP3 end of the IGFBP1/
IGFBP3 region with IGFBP-3 and IGF-I levels, and we have
discovered a novel association of some of the same variants
with circulating IGF-II, which was observed in both ProtecT
and ALSPAC. The differences found in the associations of
the polymorphisms with the biomarkers could relate to the
cohort composition (for instance, differing age structure or
sex proportion), the method of assaying blood concentrations
(e.g., physical vs. chemical dissociation of IGF-I from IGFBPs
used in ProtecT/ALSPAC and UKHLS, respectively) or to
having reduced statistical power to detect them, as ProtecT
and ALSPAC had low numbers of participants with IGF
measures.
Our ﬁndings have important implications for MR as the
SNPs examined have pleiotropic effects on IGF peptides and
it will not be possible to isolate the effect of any one bio-
marker on an outcome of interest using these instruments.
Nevertheless, these variants could be used as strong instru-
ments for the more general causal involvement of the IGF
axis on a particular trait or disease, which undoubtedly pro-
vides valuable information regarding the mechanisms leading
to the onset and progression of the condition. Because of the
regional pattern of LD and the lack of data on low frequency
variants in IGFBP1/IGFBP3 it has not been possible to fully
identify the functional polymorphisms responsible for varia-
tion in IGF levels, which could have helped better deﬁne the
instruments for MR. In the future a GWAS on circulating
IGFBP-1 might provide useful instruments for this exposure
as well.
We have also detected associations of SNPs in IGFBP-1/
IGBP-3 with prostate cancer aggressiveness which suggest a
positive relationship with higher circulating IGF-II and possi-
bly IGFBP-3 (this varies depending on the instrument used).
On the other hand, results obtained with instruments
rs11977526 and rs700752 independently indicate an inverse
association of IGF-I levels with Gleason grade and mortality.
Although these associations were not very strong it is likely
that local IGF levels in the prostate may be more prominent
and there may be other determinants of such local levels. It
is important to replicate of our ﬁndings in a non-overlapping
prostate cancer set or using stronger instruments when they
become available. Additionally, the association with mortality
deserves further scrutiny including a more thorough assess-
ment of the underlying genetic model.
Comparison with existing literature on IGF and prostate
cancer. Prior studies that have examined the relationship
between genetic variants in IGF pathway genes (primarily
IGF1 and IGFBP3) and prostate cancer, some of which also
analysed circulating IGF proteins, reported for the most part
an association of IGF1 genetic polymorphisms with disease in
Europeans, African Americans, Japanese and Chinese.37–42
Two studies, carried out in African American and Korean
men, respectively, showed an association of the IGFBP3 SNP
rs2854744 with IGFBP-3 levels and prostate cancer risk.43,44
Among the studies conducted in European populations that
measured circulating IGF-I and IGFBP-3, some found an
association of the SNPs with serum levels but not with pros-
tate cancer, and of serum levels with prostate cancer.37,45,46
Some did not ﬁnd an association of the SNPs with serum lev-
els, although both the SNPs and the serum levels were associ-
ated with prostate cancer,37,39 and one identiﬁed an
association of the genetic variants with serum levels but no
association of variants or levels with prostate cancer.39
Compared to these studies (with samples sizes ranging
from 130 to 6,000 patients and an equivalent number of
controls), our study had good power, from a large sample
size in PRACTICAL, to accurately estimate the genotype-
outcome associations, and obtain precise causal odds ratios.47
A number of observational studies have consistently
reported positive associations of circulating IGF-I with pros-
tate cancer, but inferences of causality are limited with obser-
vational studies.3,4,36 MR is designed to overcome these
problems if the exposure is adequately instrumented. Our
MR estimates with independent instruments rs11977526 and
rs700752 seem to contradict observational studies on the
effect of IGF-I on prostate cancer; however replication with,
ideally, non-pleiotropic instruments is necessary. Observatio-
nal ﬁndings for IGFBP-3 have been inconsistent,3,5,6 whereas
IGF-II and IGFBP-2 have been investigated less frequently.3,4
Regarding IGFBP-3, results based on the strongest instru-
ment (rs11977526) are concordant with the positive associa-
tion described in the observational literature4,5; however,
using another instrument, such as rs700752, suggests a pro-
tective effect. Alternatively, assuming our results represent
the effect of IGF-II on disease, they are in agreement with
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previous ﬁndings with respect to PSA-detected prostate can-
cer, although they found no evidence for an association of
this biomarker with cancer grade.4,5
Conclusions
Using MR to establish the causal effects of a modiﬁable expo-
sure, such as IGF levels, on an outcome of interest requires
genetic variants that qualify as instruments for the exposure
given a set of assumptions. Thus, it is important that strong
instruments are valid across populations, particularly as two-
sample MR becomes more common. When phenotypes are
known to vary signiﬁcantly with population characteristics it
would be desirable to make sure that they are being properly
instrumented before engaging in an MR analysis. We have
found evidence that the IGF axis contributes to some extent
to prostate cancer progression to high grade cancer and mor-
tality but the instruments currently available for circulating
IGFs do not allow us to pinpoint which biomarker or bio-
markers underlie the causal relationship.
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